The Cytori Therapeutics (CYTX) Earns Daily Media Sentiment Rating of 0.28

The Cytori Therapeutics (CYTX) Earns Daily Media Sentiment Rating of 0.28

These are some of the media headlines that may have impacted Alpha One Sentiment’s scoring:

Headlines about Cytori Therapeutics (NASDAQ:CYTX) have trended positive this week, AlphaOne Sentiment reports. The research firm, a unit of Accern, identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cytori Therapeutics earned a news sentiment score of 0.28 on AlphaOne’s scale. AlphaOne also assigned press coverage about the biotechnology company an impact score of 73 out of 100, indicating that recent press coverage is likely to have an impact on the company’s share price in the next few days.

Shares of Cytori Therapeutics (NASDAQ:CYTX) opened at 1.03 on Monday. The company’s 50-day moving average is $1.01 and its 200-day moving average is $1.45. The stock’s market cap is $33.45 million. Cytori Therapeutics has a 1-year low of $0.90 and a 1-year high of $2.48. Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. The business had revenue of $0.60 million for the quarter, compared to analyst estimates of $2.32 million. Cytori Therapeutics had a negative return on equity of 172.63% and a negative net margin of 314.07%. The business’s revenue for the quarter was down 53.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.03) earnings per share. Equities analysts expect that Cytori Therapeutics will post ($0.90) EPS for the current fiscal year.

Cytori Therapeutics Company Profile Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CYTX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Cytori Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cytori Therapeutics Inc and related companies with our FREE daily email newsletter.

Related posts

Leave a Comment